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Abstract 
Thrombospondins are encoded in vertebrates by a 
family of 5 THBS genes. THBS1 is infrequently 
mutated in most cancers, but its expression is 
positively regulated by several tumor suppressor 
genes and negatively regulated by activated 
oncogenes and promoter hypermethylation. 
Consequently, loss of thrombospondin-1 expression 
is frequently lost during oncogenesis and is 
correlated with a poor prognosis for some cancers. 
Thrombospondin-1 is a secreted protein that acts in 
the tumor microenvironment to inhibit angiogenesis, 
regulate antitumor immunity, stimulate tumor cell 
migration, and regulate the activities of extracellular 
proteases and growth factors.  
Differential effects of thrombospondin-1 on the 
sensitivity of normal versus malignant cells to 
ischemic and genotoxic stress also regulate the 
responses to tumors to therapeutic radiation and 
chemotherapy. 
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Identity 
HGNC (Hugo): THBS1 
Location: 15q14 
Other names 
THBS, TSP, THBS-1, TSP-1, TSP1 
Local order 
Telomeric to FLJ39531, centromeric to FSIP1 
(fibrous sheath interacting protein 1) 
DNA/RNA 
Description 
The THBS1 gene is 16,393 bases in size and is 
composed of 22 exons.  
Exons 2-21 encode the 5729 b mRNA. 
Transcription 
Egr-1 and Sp1 sites function in the transcription of 
THBS1 stimulated in most cell types by culture in 
the presence of serum (Shingu and Bornstein, 1994). 
Transcription is regulated by JUN (c_jun orAP1) in 
cooperation with the repressor Yin Yang-1 (YY1) 
and by TP53. 
Exon/intron organization of the THBS1 gene. 
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Domain organization and localization of selected ligand binding sites in THBS1. THBS1 is a homotrimer linked via disulfide 
bonds. 
 
USF2 and the aryl hydrocarbon receptor (AHR) 
mediate glucose-induced THBS1 transcription 
(Wang et al., 2004; Dabir et al., 2008). ID1 represses 
THBS1 transcription (Volpert et al., 2002). 
The ATF1 transcription factor also down-regulates 
transcription of THBS1 through an ATF/cAMP-
responsive element-binding protein binding site 
(Ghoneim et al., 2007). In contrast, MYC increases 
turnover of thrombospondin-1 mRNA (Janz et al., 
2000). Transcription of THBS1 in some human 
cancers is suppressed through hypermethylation (Li 
et al., 1999; Yang et al., 2003). THBS1 expression is 
also regulated post-transcriptionally by micro-RNAs 
including MIR17HG (miR-17-92), MIR18A, 
MIR19A, MIR27B, MIR98, miR-194, MIR221, and 
MIRLET7I (let-7i-5p) (van Almen et al., 2011; 
Sundaram et al.,, 2011; Italiano et al., 2012; Yang et 
al., 2019; Miao et al., 2018; Farberov and Meidan 
2018; Chen et al., 2017). 
Pseudogene 
None identified. 
Protein 
Description 
The THBS1 precursor contains 1170 amino acids; 
129,412 Da. The mature secreted protein comprises 
residues 19-1170 after removal of the N-terminal 
signal peptide and assembles into a disulfide linked 
homotrimer. Secreted THBS1 is a glycoprotein with 
a molecular mass of 150-180 kDa that contains 
approximately 12 Asn-linked mono-, bi- tri-, and 
tetraantennary complex oligosaccharides and 
variable numbers of C-mannosylated Trp residues in 
the type 1 repeats, and O-fucosylation (Furukawa et 
al., 1989; Hofsteenge et al., 2001). 
Expression 
THBS1 is expressed in many tissues during 
embryonic development but has limited expression 
in the healthy adult. THBS1 is the most abundant 
protein in alpha granules of platelets, but normal 
plasma levels are very low (typically 100-200 
ng/ml). Expression in other cell types and tissues is 
induced by wounding, ischemia, ischemia 
reperfusion, during tissue remodeling, in 
atherosclerotic lesions, rheumatoid synovium, 
glomerulonephritis, in response to high glucose and 
fat, and in the stroma of many tumors. THBS1 
expression increases with aging and in age-related 
conditions including type 2 diabetes and 
cardiovascular disease. THBS1 may also play a role 
in hematologic conditions such as sickle cell disease. 
Conversely, most but not all malignant cells in 
tumors exhibit loss of THBS1 expression during 
malignant progression (Isenberg et al., 2009). This 
loss is due to diminished positive regulation of the 
THBS1 gene by suppressor genes such as TP53 and 
NME1 and increased negative regulation by 
oncogenes including RAS and MYC. THBS1 
expression is induced by TGF-beta, vitamin A, 
progesterone, and retinoids and suppressed by 
nickel, ID1, and HGF (hepatocyte growth factor). 
Localisation 
THBS1 is secreted by many cell types in response to 
injury or specific cytokines, THBS1 is and present 
transiently in extracellular matrix but is rapidly 
internalized for degradation by fibroblasts and 
endothelial cells. THBS1 is abundant in 
megakaryocytes and platelets and is constitutively 
expressed at the dermal-epidermal boundary in skin 
and in subendothelial matrix of some blood vessels. 
However, THBS1 levels are generally low or 
undetectable in most healthy adult tissues. 
Function 
THBS1 binds to extracellular matrix ligands 
including fibrinogen, fibronectin, some collagens, 
latent and active TGFB1 (transforming growth 
factor-beta-1), TNFAIP6 (TSG6), heparin, plasmin, 
CTSG (cathepsin G), ELANE (neutrophil elastase), 
some MMPs, tissue factor pathway inhibitor, and 
heparan sulfate proteoglycans (Resovi et al., 2014). 
THBS1 binds to cell surface receptors including 
CD36, CD47, some syndecans, LRP1 (LDL 
receptor-related protein-1) (via CALR (calreticulin)) 
and the integrins ITGA5/ ITGB3 (alpha-5/beta-3), 
ITGA3/ ITGB1 (alpha-3/beta-1), ITGA4/ITGB1 
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(alpha-4/beta-1), and ITGA6/ITGB1 (alpha-6/beta-
1) (Calzada and Roberts, 2005). THBS1 is a slow 
tight inhibitor of several proteases including 
plasmin, cathepsin G, and neutrophil elastase. 
THBS1 directly binds and activates latent TGFB1 
(Murphy-Ullrich and Suto, 2018).  
THBS1 in a context-dependent and cell-specific 
manner stimulates or inhibits cell adhesion, 
proliferation, motility, and survival. THBS1 is a 
potent inhibitor of angiogenesis, but N-terminal 
proteolytic and recombinant parts of THBS1 have 
clear pro-angiogenic activities mediated by beta-1 
integrins. In the immune system, THBS1 is a potent 
inhibitor of T cell and dendritic cell activation and 
mediates clearance of apoptotic cells by phagocytes 
(Soto-Pantoja et al., 2015). In the CNS, THBS1 
secreted by astrocytes promotes synaptogenesis 
(Risher and Eroglu, 2012).  
Based on studies of Thbs1 null mice, platelet THBS1 
is not essential for platelet aggregation, but THBS1 
null mice have impaired excisional but improved 
ischemic wound repair, increased retinal 
angiogenesis, and are hyper-responsive to several 
inflammatory stimuli (Soto-Pantoja et al., 2015). 
Time stimulates pathologic production of reactive 
oxygen species (ROS) by targeting NOX1. 
Mitochondria from CD47 null mice produce less 
ROS. Inhibition of H2S signaling contributes to the 
inhibition of T cell activation by THBS1 mediated 
through the CD47 receptor (Miller et al., 2015).  
THBS1 through interacting with CD47, plays a 
broader role in primary non-cancer and cancer tissue 
survival of genotoxic damage caused by ionizing 
radiation and chemotherapy (Soto-Pantoja et al., 
2015; Feliz-Mosquea et al., 2018). Animals lacking 
either THBS1 or CD47 tolerated high-dose regional 
radiation with minimal soft-tissue injury or loss of 
bone marrow (Isenberg et al., 2008). Suppressing 
THBS1-CD47 signaling renders non-cancer cells 
and tissues resistant to radiation- and  
chemotherapy-mediated injury by promoting 
protective autophagy and enhancing anabolic 
metabolic repair pathways (Soto-Pantoja et al., 2012; 
Miller et al., 2015). Blocking the THBS1-CD47 axis 
also enhanced survival to lethal whole-body 
radiation (Soto-Pantoja et al., 2013). Conversely, 
interruption of THBS1-CD47 signaling increases 
radiation- and chemotherapy-mediated killing of 
cancers (Maxhimer et al., 2009; Feliz-Mosquea et 
al., 2018). This latter effect is mediated through 
activation of T and NK cell killing of tumors (Soto-
Pantoja et al., 2014; Nath et al., 2019).  
THBS1 is also a proximate inhibitor of stem cell self-
renewal (Kaur et al., 2013). Acting via its cell 
surface receptor CD47, THBS1 limits the expression 
of important self-renewal transcription factors 
including POU5F1 (Oct3/4), SOX2, KLF4, and 
MYC in nonmalignant cells (Kaur et al., 2013). 
However, the ability of THBS1 to limit stem cell 
self-renewal is lost in cancer cells where MYC is 
amplified or dysregulated, and loss of CD47 
expression or function consequently can suppress 
cancer stem cells (Kaur et al., 2013; Lee et al., 2014; 
Kaur and Roberts, 2016). 
Homology 
THBS1 is a member of the thrombospondin family 
that also contains THBS2, THBS3, THBS4, and 
COMP (cartilage oligomeric matrix protein) which 
arose from gene duplication of a single primordial 
thrombospondin in insects (Adams and Lawler, 
2012). The central type 1 repeats are also known as 
thrombospondin-repeats (TSRs) and are shared with 
the larger thrombospondin/properdin repeat 
superfamily (Adams and Tucker, 2000; Apte 2009; 
deLau et al., 2012). Orthologs of THBS1 are widely 
conserved in mammals and have also been identified 
in birds (Gallus gallus NP_001186382.1), 
amphibians (Xenopus tropicalis XP_002937245.1) 
and fish (Dania rerio XP_005160819.1). 
 
 
Identified mutations in thrombospondin-1 in human cancers include 187 missense (green), 41 truncating nonsense (black), 3 
inframe (brown), and 2 other (purple). Data is from The Cancer Genome Atlas (TCGA) using cBioPortal tools to analyze data 
from 10,953 patients. 
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Frequency of THBS1 mutations in TCGA PanCancer data classified by cancer type using cBioPortal tools (green = mutation, 
purple = fusion, blue = deletion, red = amplification, grey = multiple alterations). 
 
Mutations 
Germinal 
Deep exon sequencing of THBS1 from 60,706 
humans identified 4 putative loss of function 
mutations, which was significantly below the 37.6 
expected loss of function mutations for a non-
essential gene of this size (Lek et al., 2016). The 
resulting calculated probability that THBS1 is loss 
intolerant (pLI =1.0) exceeds the pLI > 0.9 cut-off, 
which predicts a strong selective pressure against 
inactivation of this gene. The basis for this apparent 
selective pressure against loss of THBS1 in humans 
remains unclear. Thbs1-/- mice are viable and fertile 
but exhibit defects in inflammatory responses and 
wound repair that may compromise their viability 
outside a protected laboratory environment (Lawler 
et al., 1998; Crawford et al., 1998; Lamy et al., 2007; 
Qu et al., 2018). Coding polymorphisms in THBS1 
associated with altered disease risk in humans 
include a2210g (Asn700Ser), which is associated 
with premature familial myocardial infarction and 
small for gestational age infants. This mutation alters 
calcium binding to THBS1 and protein stability 
(Carlson et al., 2008; Hannah et al., 2004). The 
coding polymorphism g1678a (Thr523Ser) was 
identified as a genetic risk factor of cerebral 
thrombosis in a Chinese population (Liu et al., 
2004). Several noncoding SNPs in THBS1 have 
been associated with cancer risk as detailed below. 
Somatic 
The frequency of somatic THBS1 mutation in 
human cancers is low. Somatic mutations have been 
identified at a frequency of 1.9% in The Cancer 
Genome Atlas (cbioprortal.org). A total of 233 
mutations have been identified, most of which are 
missense or nonsense. However, the random 
distribution of these mutations indicates a lack of 
cancer-specific mutation hotspots. THBS1 is most 
frequently mutated in cutaneous melanomas (12%) 
followed by uterine cancers (7%), but rare or absent 
in other cancer types. The higher mutation rate of 
THBS1 in melanomas may simply reflect the high 
overall mutation burden of this malignancy. 
Epigenetics 
Most down-regulation of THBS1 in cancers is 
epigenetic, resulting from promoter 
hypermethylation (Yang et al., 2003), altered 
expression of regulatory noncoding RNAs (van 
Almen et al., 2011; Sundaram et al., 2011; Italiano  
et al., 2012; Yang et al., 2019; Miao et al., 2018; 
Farberov and Meidan 2018; Chen et al., 2017), or 
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altered levels of oncogenic transcription factor. 
Epigenetic silencing of THBS1 is associated with a 
poor prognosis in several cancers (Guerrero et al., 
2008; Isenberg et al., 2009). 
Implicated in 
Gastric carcinoma 
Disease 
THBS1 rs1478605 T>C 
Carriers of the CC genotype exhibited a decreased 
risk of developing gastric cancer compared to the 
carriers of the CT and TT genotypes [adjusted OR, 
0.56; 95% confidence interval (CI), 0.39-0.79; 
P=0.001] (Hong et al., 2015). The CC genotype of 
rs1478605 was negatively associated with gastric 
cancer lymph node metastasis (OR, 0.41; 95% CI, 
0.23-0.71; P=0.001) and was associated with a 
reduced risk of lymph node metastasis in male 
patients (OR, 0.27; 95% CI, 0.14-0.52; P 
THBS1 rs2292305 T>C, rs1478604 A>G 
Significant association was found between the 
homozygous CC variant of THBS1 (rs2292305 
T>C) and development of highly differentiated 
gastric carcinoma (Lin et al., 2012). The rs1478604 
A>G variant was associated with invasion and 
lymph node metastasis in gastric cancer. Based on 
logistic regression and stratification analysis, 
rs1478604 A>G was more strongly associated with 
lymph node metastasis in highly differentiated 
gastric cancer. 
Oncogenesis 
The mechanism by which this polymorphism 
regulates carcinogenesis remains to be determined. 
Bladder cancer 
Disease 
THBS1 696 C/T polymorphism (rs2664139) 
Compared with the CT/TT genotypes, the CC 
genotype was associated with a significantly 
increased risk of bladder cancer (adjusted odds ratio 
[OR] 1.43, 95% CI 1.01-2.04) (Gu et al., 2014). 
Oncogenesis 
The mechanism by which this polymorphism 
regulates carcinogenesis remains to be determined. 
Colorectal cancer 
Cancer progression associated with loss of THBS1 
expression in the absence of known gene mutations. 
Prognosis 
Mutation of THBS1 is rare in most cancers, but loss 
of THBS1 expression due to hypermethylation, 
transcriptional regulation by oncogenes or tumor 
suppressor genes, or altered mRNA stability is 
commonly reported (Isenberg et al., 2009). 
Decreased THBS1 expression has been correlated 
with malignant progression and decreased survival 
in several cancers (Isenberg et al., 2009). To date, the 
strongest data is for colorectal carcinomas. Multiple 
independent studies have shown significant 
association of reduced THBS1 expression with 
increased invasion, microvascular densities, and 
poor prognosis (Miyanaga et al., 2002; Maeda et al., 
2001; Isenberg et al., 2009; Teraoku et al., 2016). 
Increased circulating levels of THBS1 were also a 
favourable prognostic marker in patients with colon 
cancer (HR 0.43, p = 0.007) (Marisi et al., 2018). 
Oncogenesis 
The specific role of THBS1 in colorectal 
oncogenesis has been studied in the APCMin/+ mouse 
model. Mice lacking THBS1 on the ApcMin/+ 
background exhibited increased intestinal adenoma 
formation with increased vascularization compared 
to Thbs1+/+: ApcMin/+ mice, consistent with the 
known anti-angiogenic activity of THBS1 (Gutierrez 
et al., 2003). Lack of THBS1 also decreased 
colorectal carcinogenesis in mice exposed to the 
carcinogen azoxymethane in combination with oral 
administration of dextran sulfate to induce intestinal 
inflammation (Lopez-Dee, et al., 2015). Again, 
angiogenesis was increased in the lesions formed in 
the Thbs1-/- mice. However, the protective role of 
THBS1 expression to limit colorectal carcinogenesis 
was lost when ApcMin/+ mice were fed a high fat 
Western diet, and metabolomic analysis identified 
systemic alterations including in eicosanoid 
metabolism that may mediate this effect (Soto-
Pantoja et al., 2016). 
Various cancers 
Disease 
Cancer progression associated with loss of THBS1 
expression in the absence of known gene mutations. 
Prognosis 
Studies have shown associations of decreased 
THBS1 with poor prognosis in various cancers 
including non-small cell lung carcinoma (Rouanne et 
al., 2016), pancreatic adenocarcinoma, gastric 
(Nakao, et al., 2011), invasive cervical carcinoma, 
and oral squamous cell carcinomas (Isenberg et al., 
2009). Reports are mixed regarding THBS1 as a 
prognostic factor in breast cancers (Rice et al., 2002). 
Stromal THBS1 expression in breast cancer was 
inversely related to lymph node involvement 
(Ioachim et al., 2012). Evidence indicates that the 
failure of THBS1 to protect in breast cancer is due to 
an escape mechanism involving increased VEGFA 
expression (Fontana et al., 2005). Hypermethylation 
of THBS1 was associated with a poor prognosis in 
prostate cancers (Guerrero et al., 2008). However, 
THBS1 was positively correlated with invasion in 
hepatocellular carcinomas (Poon et al 2004). 
Evidence is mixed regarding the clinical significance 
of THBS1 expression in prostate cancer, and 
urothelial cancer (Miyata and Sakai, 2013). 
Oncogenesis 
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Several transgenic mouse models support an indirect 
tumor suppressor activity of THBS1. Mice lacking 
THBS1 developed tumors earlier in a tp53 null 
background (Lawler et al., 2001). Loss of THBS1 
expression was associated with local invasive 
behavior, tumor neovascularization, and metastasis. 
A study of UVB-induced skin carcinogenesis in 
wildtype versus Thbs1-/- hairless SKH1 mice found 
that the protective activity of the flavone apigenin 
was lost in the absence of THBS1 (Mirzoeva et al., 
2018). The protective role of THBS1 to limit 
carcinogenesis in skin was associated with decreased 
levels of circulating inflammatory cytokines and 
infiltrating macrophages and neutrophils.  
Conversely, transgenic mice overexpressing THBS1 
in skin or mammary tissue were resistant to chemical 
or oncogene-driven carcinogenesis (Streit et al., 
1999; Rodriguez-Manzaneque et al., 2001). In 
addition to inhibiting the angiogenic switch required 
for tumor growth and hematologic metastasis, over-
expression of THBS1 in tumor cells was associated 
with increased M1 polarization of tumor-associated 
macrophages in xenograft tumors, and THBS1 
treatment increased superoxide production and 
killing of tumor cells by macrophages in vitro 
(Martin-Manos et al., 2008). 
Familial pulmonary artery 
hypertension 
Disease 
THBS1 missense mutant Asp362Asn 
The THBS1 missense mutation (Asp362Asn) alters 
a residue in the first type 1 repeat of THBS1 
(Maloney et al., 2012). The Asp362Asn THBS1 
mutant had less than half of the ability of wild-type 
THBS1 to activate latent TGFB1. Mutant 362Asn 
THBS1 also lost the ability to inhibit growth of 
pulmonary arterial smooth muscle cells and was over 
three-fold less effective at inhibiting endothelial cell 
growth.  
The mutation was found in two unrelated probands 
from 60 familial pulmonary arterial hypertension 
(PAH) kindreds but not in any healthy or chronic 
disease control cohorts. Several affected family 
members carried a mutation in BMPR2, which is 
known to be associated with PAH risk, and one 
family member with the THBS1 mutation but 
lacking the BMPR2 mutation was not diagnosed 
with PAH. Therefore, the THBS1 mutation alone 
may not be sufficient to cause PAH, and THBS1 was 
proposed to be a modifier gene for familial PAH. 
The frequency of other common THBS1 
polymorphisms did not differ between PAH and 
control cohorts.  
THBS1 intronic mutation (IVS8+255 G/A)  
THBS1 intronic mutation (IVS8+255 G/A) was 
identified in a proband with familial pulmonary 
hypertension (Maloney et al., 2012). This mutation 
decreased and/or eliminated local binding of the 
transcription factors SP1 and MAZ in aortic smooth 
muscle cells. The mutation was confirmed to not 
alter splicing of THBS1 mRNA but is predicted to 
alter gene expression.  
The mutation was found in multiple members of the 
single proband family with nine members diagnosed 
with PAH but absent in healthy and chronic disease 
control cohorts. Some of the affected family 
members were known to have BMPR2 mutations 
that are associated with PAH risk, and two family 
members with the THBS1 mutation but lacking the 
BMPR2 mutation were not diagnosed with PAH. 
Therefore, THBS1 was proposed to be a modifier 
gene. Because only one family was reported to date, 
the relative risk associated with this mutation 
remains to be determined. 
Post-refractive surgery chronic 
ocular surface inflammation 
Disease 
 THBS1 SNPs (rs1478604 T >?C, rs2228262 
missense AAT> AGT, rs2292305 missense ACA> 
GCA)  
Increased risk for developing chronic inflammation 
in patients undergoing refractive eye surgery or 
receiving corneal allografts. 
Prognosis 
Patients with the minor alleles were more susceptible 
to developing chronic keratoconjunctivitis 
(rs1478604: odds ratio [OR], 2.5; 95% confidence 
interval [CI], 1.41-4.47; P = 2.5 × 10-3; rs2228262 
and rs2292305: OR, 1.9; 95% CI, 1.05-3.51; P = 4.8 
× 10-2.  The rs1478604 A SNP was significantly 
associated with increased risk of corneal allograft 
rejection (odds ratio [OR], 1.58; 95% confidence 
interval [CI], 1.02-2.45; P = 0.04) (Contreras-Ruiz et 
al., 2014; Winton et al., 2014 
Familial premature myocardial 
infarction, Small for gestational age 
(SGA) infants 
Disease 
 THBS1 variant A2210G (Ser700Asn)  
The THBS1 S700N variant is a significant risk factor 
for familial premature myocardial infarction in both 
homozygous and heterozygous carriers of the variant 
allele (Topol et al., 2001; Zwicker et al., 2006; 
Stenina et al., 2004).  
Paternal and neonatal THBS1 A2210G was also 
associated with small gestational age. Maternal 
THBS1 A2210G was associated with reduced 
maternal birth weight adjusted for gestational age at 
delivery (P = 0.03) (Andraweera et al., 2011). 
Prognosis 
The THBS1 S700N variant may be a general risk 
factor for vascular disorders throughout life. 
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Sickle cell disease 
Disease 
 THBS1 SNPs (rs1478605 T > C and rs1478604 T 
> C)  
The THBS1 SNPs rs1478604 (minor allele 
frequencies (MAF) 0.291) and rs1478605 (MAF 
0.286) were negatively associated [OR 0.45 (95% CI 
0.19, 1.08; p=0.069) and OR 0.33 (95% CI 0.12, 
0.88; p=0.017, respectively)] with tricuspid 
regurgitant velocity (TRV) ≥2.5 in sickle cell disease 
patients (Jacob et al., 2017). Elevated TRV is a 
marker of pulmonary dysfunction. Of note, 
rs1478605 and rs1478604 are proximal to the 
THBS1 transcription start site and may alter THBS1 
expression in patients with sickle cell disease. 
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